This is a preview of subscription content, log in via an institution to check access.
Reference
European Commission. Antitrust: Commission welcomes continued low level of potentially problematic patent settlements in EU pharma sector. Media Release : 9 Dec 2013. Available from: URL: http://europa.eu
Additional information
* i.e. pay-for delay deals where generic companies receive payments for delaying the launch of generic versions of branded drugs
Rights and permissions
About this article
Cite this article
Pharma patent settlements in EU continue to rise. PharmacoEcon Outcomes News 693, 10 (2013). https://doi.org/10.1007/s40274-013-0948-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0948-7